Opportunities for Healthy Volunteers

Contribute to medical research by participating in studies designed for healthy participants in your selected area.

Matched clinical trials

  • Study on the Safety and Effects of Volrustomig and Axitinib for Patients with Advanced Kidney Cancer

    Not recruiting

    1 1 1 1
    Investigated Diseases:
    Investigated Drugs:
    France Spain
  • Study of Belzutifan and Palbociclib for Patients with Advanced Renal Cell Carcinoma

    Not recruiting

    1 1 1 1
    Investigated Diseases:
    Investigated Drugs:
    France Germany Italy Poland Spain Sweden
  • Study on Atezolizumab and Drug Combinations for Advanced Malignancies in Patients from Previous Atezolizumab Trials

    Not recruiting

    3 1 1 1
    Belgium Czechia France Germany Greece Hungary +5
  • Study of Pembrolizumab, Favezelimab, and Lenvatinib for Patients with Renal Cell Carcinoma

    Not recruiting

    1 1 1 1
    France Hungary The Netherlands Poland Spain
  • Study of BGB-A425, LBL-007, and Tislelizumab for Patients with Advanced Head and Neck Cancer, Lung Cancer, or Kidney Cancer

    Not recruiting

    2 1 1
    France Italy Poland Spain
  • Study on the Safety and Effectiveness of Pembrolizumab for Patients with Kidney Cancer After Surgery

    Not recruiting

    3 1 1
    Investigated Diseases:
    Czechia Finland France Germany Ireland Italy +3
  • Study of Subcutaneous Nivolumab with or without Recombinant Human Hyaluronidase PH20 for Patients with Lung, Kidney, Melanoma, Liver, Colorectal, or Bladder Cancer

    Not recruiting

    1 1 1 1
    Investigated Drugs:
    France Italy The Netherlands Poland Spain
  • Study of Pembrolizumab and Lenvatinib for Patients with Advanced Non-Clear Cell Kidney Cancer

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    Investigated Drugs:
    France Hungary Italy Poland Spain
  • Study of Pembrolizumab, Belzutifan, and Lenvatinib for Patients with Advanced Clear Cell Renal Cell Carcinoma

    Not recruiting

    3 1 1 1
    Croatia Czechia Denmark Finland France Germany +8
  • Study Comparing Tivozanib and Nivolumab Combination to Tivozanib Alone in Patients with Renal Cell Carcinoma After Previous Immune Therapy

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    Investigated Drugs:
    Belgium Czechia France Germany Italy Poland +2